New ESMO Guideline: Oncogene-Addicted #mNSCLC. Developed due to rapid advances in biomarker identification & targeted therapies; updated recommendations & tx algorithms on new & clinically relevant biomarker identification, targeting & adv disease managemt ow.ly/uV7X50MyPeA

An excellent manuscript on ALK-positive NSCLC with brain metastases #LCSM. Read it here 👇

🆕🗞️Out in the Lung Cancer Journal an excellent review investigating *Primary endpoints to assess the efficacy of novel therapeutic approaches in EGFR-mutated, surgically resectable NSCLC #LCSM lungcancerjournal.info/article/S0169-…

Have you registered for #BTOG23 yet? Our fantastic programme of expert speakers is available on our website. Join us in Belfast for this event that's not to be missed by anyone working in the field of #LungCancer ow.ly/uY9S50MVp0k

🚨just out in Lung Cancer Journal MET Alterations in Advanced NSCLC METCrusaders #LCSM lungcancerjournal.info/article/S0169-…

Age-period-cohort effect on lung cancer mortality in Spain, 1982-2021 #LCSM 🇪🇸 lungcancerjournal.info/article/S0169-…

TROP2 expression and SN38 antitumor activity in malignant pleural #mesothelioma cells provide a rationale for antibody-drug conjugate therapy #LCMS #meso lungcancerjournal.info/article/S0169-…

🚨just out in Lung Cancer Journal this important review lead by Martin Reck discussing the role of anti-angiogenic agents for the treatment of resistant NSCLC: rationale, recent updated and perspectives #LCSM 🔗 sciencedirect.com/science/articl…

The European Lung Cancer Congress is ready to start in a few of days *Official hashtag: #ELCC23 👈🏻

🚨🆕 Just out in Lung Cancer Journal this review by Mariana Brandao et al, discussing “Systemic treatment & radiotherapy for pts with NSCLC & #HIV infection” #LCSM Find it here 🔗lungcancerjournal.info/article/S0169-…

See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, @ESMO_IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60114dyyV

🆕Just out in Lung Cancer Journal this interesting editorial by Jarushka Naidoo & . Francesco Cortiula discussing the role of neoadjuvant Osimertinib in resectable NSCLC, harbouring EGFR mutations #LCSM Here the link: lungcancerjournal.info/article/S0169-…

💡#LCSM a new review by Patrick Forde and colleagues, not to be missed!! Neoadjuvant immunotherapy in NSCLC!!! 🚨 lungcancerjournal.info/action/consume…

Happy to see our work on KL-6/MUC1 in pleural meso now out in Lung Cancer Journal: ➤ KL-6 lvls in pleural eff were diagnostic in 2 indep cohorts of pts with pleural meso. ➤⬆️KL-6 lvls and ⬆️MUC1 mRNA expression were associated with⬆️patient outcome. 👉lungcancerjournal.info/article/S0169-…

See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, @ESMO_IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60134dyVR

Current Trial Report on the TARGET trial TARGET is a phase II, open-label, single-arm study of 5-year adjuvant #osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC Primary endpoint: investigator-assessed DFS at 5 years More: bit.ly/46P0VcO

Outcomes with chemo-immunotherapy by #KRAS, STK11, and KEAP1 across PDL1 strata Lung Cancer Journal. KRAS mt enriched in PDL1 high but KRAS with co-mutations in STK11 and KEAP1 enriched in PDL1 negative. Poor OS in KRAS mt with PDL1 0% driven by STK11/KEAP1. lungcancerjournal.info/article/S0169-…

🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib Link here 👉lungcancerjournal.info/article/S0169-… #LCSM ALK Positive

Stephen V Liu, MD Lung Cancer Journal Disappointing results from LU17-19 study. Osimertinib's lack of response is a setback. We need better treatment options, especially for specific exon 20 insertion mutations

We are pleased to announce that our journal now accepts *Trial in Progress (TiP) papers*, including ongoing phase II and III trials registered with NCI's Clinical Trials Reporting Program. All submission guidelines are available here 🔗sciencedirect.com/journal/lung-c…